Cargando…

Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease

Cardiovascular diseases (CVDs) comprise 45% of all deaths in Europe and causes 3.9 million deaths annually. Coronary artery disease (CAD) which includes myocardial infarction (MI) represents the most common form of CVD. A relevant proportion of MI cases seems preventable since reports claim that up...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrivastava, Apurva, Marzolla, Vincenzo, Weidmann, Henri, Caprio, Massimiliano, Tregouet, David-Alexandre, Zeller, Tanja, Karakas, Mahir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022893/
https://www.ncbi.nlm.nih.gov/pubmed/31940748
http://dx.doi.org/10.3390/biom10010125
_version_ 1783498122859642880
author Shrivastava, Apurva
Marzolla, Vincenzo
Weidmann, Henri
Caprio, Massimiliano
Tregouet, David-Alexandre
Zeller, Tanja
Karakas, Mahir
author_facet Shrivastava, Apurva
Marzolla, Vincenzo
Weidmann, Henri
Caprio, Massimiliano
Tregouet, David-Alexandre
Zeller, Tanja
Karakas, Mahir
author_sort Shrivastava, Apurva
collection PubMed
description Cardiovascular diseases (CVDs) comprise 45% of all deaths in Europe and causes 3.9 million deaths annually. Coronary artery disease (CAD) which includes myocardial infarction (MI) represents the most common form of CVD. A relevant proportion of MI cases seems preventable since reports claim that up to two-thirds of these patients exhibit symptoms suggestive for MI within 12 months prior to the acute MI event. An early identification of these at-risk subjects is necessary to manage an early and efficient treatment during the ischemic phase. The aim of the PRecision MEDicine in Coronary Artery Disease (PREMED-CAD) consortium is to apply a system medicine approach towards studying and identifying an ischemia specific ‘biomarker signature’ that improves the identification of individuals ‘at-risk’ for acute MI. The consortium will take an interdisciplinary and translational approach integrating knowledge from CAD epidemiology, imaging, bioinformatics, statistics and molecular biology, as well as existing phenotypic, blood-based and clinical biomarker data of distinct CAD and subclinical MI phenotypes. This biomarker signature will be validated through atherosclerosis-prone mouse models and human cohorts. The validated signature will be translated in a real-world clinical setting using an ongoing clinical trial comprising patients with subclinical ischemia. The aim of the knowledge obtained from this project is to aid in early MI detection and reduce the mortality and morbidity rate in these at-risk MI individuals.
format Online
Article
Text
id pubmed-7022893
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70228932020-03-12 Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease Shrivastava, Apurva Marzolla, Vincenzo Weidmann, Henri Caprio, Massimiliano Tregouet, David-Alexandre Zeller, Tanja Karakas, Mahir Biomolecules Concept Paper Cardiovascular diseases (CVDs) comprise 45% of all deaths in Europe and causes 3.9 million deaths annually. Coronary artery disease (CAD) which includes myocardial infarction (MI) represents the most common form of CVD. A relevant proportion of MI cases seems preventable since reports claim that up to two-thirds of these patients exhibit symptoms suggestive for MI within 12 months prior to the acute MI event. An early identification of these at-risk subjects is necessary to manage an early and efficient treatment during the ischemic phase. The aim of the PRecision MEDicine in Coronary Artery Disease (PREMED-CAD) consortium is to apply a system medicine approach towards studying and identifying an ischemia specific ‘biomarker signature’ that improves the identification of individuals ‘at-risk’ for acute MI. The consortium will take an interdisciplinary and translational approach integrating knowledge from CAD epidemiology, imaging, bioinformatics, statistics and molecular biology, as well as existing phenotypic, blood-based and clinical biomarker data of distinct CAD and subclinical MI phenotypes. This biomarker signature will be validated through atherosclerosis-prone mouse models and human cohorts. The validated signature will be translated in a real-world clinical setting using an ongoing clinical trial comprising patients with subclinical ischemia. The aim of the knowledge obtained from this project is to aid in early MI detection and reduce the mortality and morbidity rate in these at-risk MI individuals. MDPI 2020-01-11 /pmc/articles/PMC7022893/ /pubmed/31940748 http://dx.doi.org/10.3390/biom10010125 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Concept Paper
Shrivastava, Apurva
Marzolla, Vincenzo
Weidmann, Henri
Caprio, Massimiliano
Tregouet, David-Alexandre
Zeller, Tanja
Karakas, Mahir
Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease
title Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease
title_full Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease
title_fullStr Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease
title_full_unstemmed Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease
title_short Design and Rationale of the ERA-CVD Consortium PREMED-CAD—Precision Medicine in Coronary Artery Disease
title_sort design and rationale of the era-cvd consortium premed-cad—precision medicine in coronary artery disease
topic Concept Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022893/
https://www.ncbi.nlm.nih.gov/pubmed/31940748
http://dx.doi.org/10.3390/biom10010125
work_keys_str_mv AT shrivastavaapurva designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease
AT marzollavincenzo designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease
AT weidmannhenri designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease
AT capriomassimiliano designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease
AT tregouetdavidalexandre designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease
AT zellertanja designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease
AT karakasmahir designandrationaleoftheeracvdconsortiumpremedcadprecisionmedicineincoronaryarterydisease